Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Stopped Withdrawn because there were no dramatic changes in the main endpoint, as well as low enrollment numbers. The data are not interpretable in terms of efficacy.

Conditions

• Leukemia

Interventions

• BIOLOGICAL: bcr-abl peptide vaccine
• GENETIC: reverse transcriptase-polymerase chain reaction

Sponsor

OHSU Knight Cancer Institute

Collaborators

• [object Object]